Summary University Of Queensland (UQ) is a research institute.The university manages personal, career, welfare and learning issues.
It conducts research in the areas of physical sciences, biological sciences, technology, biomedical and clinical health sciences, engineering, chemical sciences and environmental sciences, among others.UQ provides educational courses in the areas of arts, architecture and information technology, business, economics and law, social and behavioural sciences.
The university conducts research services through its research institutes.It also offers support to research higher degree students through a broad range of scholarships and research travel awards.
UQ is headquartered in Brisbane, Queensland, Australia.
University of Queensland - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
216 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Multiple Myeloma Therapeutics Market to Reach $27.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Multiple Myeloma Therapeutics estimated at US$9.9 Billion in the year 2020, is projected to reach a revised size of US$27.1 Billion by 2027, growing at a CAGR of 15.5% over the analysis...
Liposarcoma (Oncology) - Drugs in Development, 2021 Summary Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis...
Dedifferentiated Liposarcoma (Oncology) - Drugs in Development, 2021 Summary Dedifferentiated Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Dedifferentiated Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under...
Carcinomas (Oncology) - Drugs in Development, 2021 Summary Carcinomas (Oncology) - Drugs in Development, 2021 provides an overview of the Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Carcinomas, complete with analysis...
Melanoma - Epidemiology Forecast to 2029
Summary
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drugs in Development, 2021 Summary Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor...
Colon Carcinoma (Oncology) - Drugs in Development, 2021 Summary Colon Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete...
High-Grade Glioma (Oncology) - Drugs in Development, 2021 Summary High-Grade Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma,...
Non-Small Cell Lung Carcinoma (Oncology) - Drugs in Development, 2021 Summary Non-Small Cell Lung Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics...
Cancer
Therapy
Research And Development
World
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.